Pharmaron | Pharmaron API Commercial Synthesis Cramlington (UK)

The Pharmaron Cramlington site, located in Northumberland, UK, was acquired by Pharmaron in 2022, significantly enhancing the company’s technologies and capabilities.

Cramlington is an FDA-, EMA-, MHRA-, and PMDA-approved facility, equipped with reactors ranging from 50 L to 10,000 L. It supports batch sizes from just a few grams to several hundred kilograms, covering the full spectrum from clinical development to commercial manufacturing.

The site comprises two kilo labs, a pilot plant (250 L to 1,000 L), and two commercial-scale buildings (3,000 L to 10,000 L), offering a total reactor capacity of 170,000 L.

Fully integrated into the Pharmaron global network, the Cramlington site is backed by a team of 250 process chemists based in the UK. It also plays a key role in Pharmaron’s successful hybrid model between China and the UK: advanced intermediates are produced in China, shipped to Cramlington, and converted into final APIs in the UK.This model ensures a robust, flexible supply chain while maintaining cost-efficiency (COGs).